What's new? Log in Free sign up

Arcellx (ACLX)

Company Profile

Company profile

Ticker

ACLX

Exchange

Website

CEO

Mr. Rami Elghandour

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Moderna • Bio-Techne • Acorda Therapeutics • Saratoga Investment ...

Former names

Columbia Care Inc.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Subdomain, LLC ...

IRS number

472855917

ACLX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$117.00

Low target

$105.00

High target

$136.00

Truist Securities

HC Wainwright & Co.

Piper Sandler

Maintains

Overweight

$115.00

8 Nov 24

Needham

Maintains

Buy

$105.00

8 Nov 24

Latest filings (excl ownership)

View all

Registration of securities for employees

Quarterly report

7 Nov 24

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual

Quarterly report

8 Aug 24

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Submission of Matters to a Vote of Security Holders

Quarterly report

9 May 24

Latest ownership filings

View all

Christopher Heery

Michelle Gilson

Rami Elghandour

Christopher Heery

Michelle Gilson

Rami Elghandour

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart ACLX financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	164.47 mm	164.47 mm	164.47 mm	164.47 mm	164.47 mm	164.47 mm
Cash burn (monthly)	(no burn)	(no burn)	11.21 mm	5.33 mm	(no burn)	(no burn)
Cash used (since last report)	n/a	n/a	47.72 mm	22.70 mm	n/a	n/a
Cash remaining	n/a	n/a	116.75 mm	141.77 mm	n/a	n/a
Runway (months of cash)	n/a	n/a	10.4	26.6	n/a	n/a

Beta Read what these cash burn values mean

Financial data from Arcellx earnings reports.

Institutional ownership, Q3 2024

ACLX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	190	172	+10.5%
Opened positions	37	27	+37.0%
Closed positions	19	33	-42.4%
Increased positions	68	77	-11.7%
Reduced positions	60	48	+25.0%

13F shares	Current	Prev Q	Change
Total value	3.80 tn	2.55 tn	+48.7%
Total shares	62.30 mm	63.06 mm	-1.2%
Total puts	907.30 k	53.70 k	+1589.6%
Total calls	2.23 mm	95.90 k	+2229.8%
Total put/call ratio	0.4	0.6	-27.5%

Largest owners	Shares	Value	Change
GILD Gilead Sciences	6.72 mm	$0.00	0.0%
FMR	6.48 mm	$541.08 bn	-0.1%
BlackRock	4.25 mm	$354.64 bn	NEW
Paradigm Biocapital Advisors	4.00 mm	$334.04 bn	+3.9%
Perceptive Advisors	3.89 mm	$324.74 bn	-0.0%
NEA Management	3.75 mm	$312.77 bn	0.0%
New Enterprise Associates 15	3.75 mm	$165.99 mm	0.0%
Vanguard	2.46 mm	$205.61 bn	+7.2%
SR One Capital Management	2.35 mm	$169.05 mm	0.0%
SR One Capital Management	2.35 mm	$195.97 bn	0.0%

Largest transactions	Shares	Bought/sold	Change
BlackRock	4.25 mm	+4.25 mm	NEW
BLK BlackRock	0.00	-3.52 mm	EXIT
Suvretta Capital Management	689.95 k	-826.30 k	-54.5%
Great Point Partners	100.00 k	-392.00 k	-79.7%
Cormorant Asset Management	1.25 mm	-275.00 k	-18.0%
T. Rowe Price	1.90 mm	+269.92 k	+16.6%
Partner Fund Management	60.60 k	-251.38 k	-80.6%
Ra Capital Management	1.85 mm	+247.47 k	+15.4%
T. Rowe Price Investment Management	944.64 k	-229.15 k	-19.5%
StemPoint Capital	60.08 k	-220.63 k	-78.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ACLX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
4 Feb 25	Kavita Patel	Common Stock	Sell	Dispose S	No	Yes	64.57	1,500	96.85 k	0
4 Feb 25	Kavita Patel	Common Stock	Option exercise	Acquire M	No	No	6.66	1,500	9.99 k	1,500
4 Feb 25	Kavita Patel	Stock Option Common Stock	Option exercise	Dispose M	No	No	6.66	1,500	9.99 k	36,077
14 Jan 25	Kavita Patel	Common Stock	Sell	Dispose S	No	Yes	67.3167	300	20.20 k	0
14 Jan 25	Kavita Patel	Common Stock	Sell	Dispose S	No	Yes	66.6225	400	26.65 k	300
14 Jan 25	Kavita Patel	Common Stock	Sell	Dispose S	No	Yes	64.9465	800	51.96 k	700
14 Jan 25	Kavita Patel	Common Stock	Option exercise	Acquire M	No	No	6.66	1,500	9.99 k	1,500
14 Jan 25	Kavita Patel	Stock Option Common Stock	Option exercise	Dispose M	No	No	6.66	1,500	9.99 k	37,577
8 Jan 25	Rami Elghandour	Common Stock	Sell	Dispose S	No	No	73.6929	13,837	1.02 mm	117,275
8 Jan 25	Michelle Gilson	Common Stock	Sell	Dispose S	No	No	73.6929	3,997	294.55 k	9,582

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

(ACLX) - Analyzing Arcellx's Short Interest

UBS Maintains Buy on Arcellx, Raises Price Target to $114

UBS analyst Ashwani Verma maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $106 to $114.

HC Wainwright & Co. Reiterates Buy on Arcellx, Maintains $115 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Arcellx (NASDAQ:ACLX) with a Buy and maintains $115 price target.

Needham Reiterates Buy on Arcellx, Maintains $105 Price Target

In-Depth Examination Of 14 Analyst Recommendations For Arcellx

Press releases

From Benzinga Pro

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

-- Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months -- -- No delayed neurotoxicities have been

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.